These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 21712434)

  • 1. Pharmacokinetic and pharmacodynamic modeling of the effect of an sodium-glucose cotransporter inhibitor, phlorizin, on renal glucose transport in rats.
    Yamaguchi K; Kato M; Suzuki M; Asanuma K; Aso Y; Ikeda S; Ishigai M
    Drug Metab Dispos; 2011 Oct; 39(10):1801-7. PubMed ID: 21712434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro-in vivo correlation of the inhibition potency of sodium-glucose cotransporter inhibitors in rat: a pharmacokinetic and pharmacodynamic modeling approach.
    Yamaguchi K; Kato M; Suzuki M; Hagita H; Takada M; Ayabe M; Aso Y; Ishigai M; Ikeda S
    J Pharmacol Exp Ther; 2013 Apr; 345(1):52-61. PubMed ID: 23386251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
    Nagata T; Fukazawa M; Honda K; Yata T; Kawai M; Yamane M; Murao N; Yamaguchi K; Kato M; Mitsui T; Suzuki Y; Ikeda S; Kawabe Y
    Am J Physiol Endocrinol Metab; 2013 Feb; 304(4):E414-23. PubMed ID: 23249697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+/H+ exchanger isoform 3 activity in the renal proximal tubule.
    Pessoa TD; Campos LC; Carraro-Lacroix L; Girardi AC; Malnic G
    J Am Soc Nephrol; 2014 Sep; 25(9):2028-39. PubMed ID: 24652792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
    Yoshii A; Nagoshi T; Kashiwagi Y; Kimura H; Tanaka Y; Oi Y; Ito K; Yoshino T; Tanaka TD; Yoshimura M
    Cardiovasc Diabetol; 2019 Jul; 18(1):85. PubMed ID: 31262297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A fluorescence method for measurement of glucose transport in kidney cells.
    Blodgett AB; Kothinti RK; Kamyshko I; Petering DH; Kumar S; Tabatabai NM
    Diabetes Technol Ther; 2011 Jul; 13(7):743-51. PubMed ID: 21510766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural selectivity of human SGLT inhibitors.
    Hummel CS; Lu C; Liu J; Ghezzi C; Hirayama BA; Loo DD; Kepe V; Barrio JR; Wright EM
    Am J Physiol Cell Physiol; 2012 Jan; 302(2):C373-82. PubMed ID: 21940664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Competitive inhibition of SGLT2 by tofogliflozin or phlorizin induces urinary glucose excretion through extending splay in cynomolgus monkeys.
    Nagata T; Suzuki M; Fukazawa M; Honda K; Yamane M; Yoshida A; Azabu H; Kitamura H; Toyota N; Suzuki Y; Kawabe Y
    Am J Physiol Renal Physiol; 2014 Jun; 306(12):F1520-33. PubMed ID: 24761001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual SGLT1/SGLT2 inhibitor phlorizin reduces glucose transport in experimental peritoneal dialysis.
    Martus G; Bergling K; Öberg CM
    Perit Dial Int; 2023 Mar; 43(2):145-150. PubMed ID: 35188009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of SGLT1 and SGLT2 inhibitors.
    Rieg T; Vallon V
    Diabetologia; 2018 Oct; 61(10):2079-2086. PubMed ID: 30132033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.
    Katsuno K; Fujimori Y; Takemura Y; Hiratochi M; Itoh F; Komatsu Y; Fujikura H; Isaji M
    J Pharmacol Exp Ther; 2007 Jan; 320(1):323-30. PubMed ID: 17050778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the transport activity of SGLT2/MAP17, the renal low-affinity Na
    Coady MJ; Wallendorff B; Lapointe JY
    Am J Physiol Renal Physiol; 2017 Aug; 313(2):F467-F474. PubMed ID: 28592437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic modeling for the effect of sodium-glucose cotransporter inhibitors on blood glucose level and renal glucose excretion in db/db mice.
    Yamaguchi K; Kato M; Ozawa K; Kawai T; Yata T; Aso Y; Ishigai M; Ikeda S
    J Pharm Sci; 2012 Nov; 101(11):4347-56. PubMed ID: 22927193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a novel non-radioactive cell-based method for the screening of SGLT1 and SGLT2 inhibitors using 1-NBDG.
    Chang HC; Yang SF; Huang CC; Lin TS; Liang PH; Lin CJ; Hsu LC
    Mol Biosyst; 2013 Aug; 9(8):2010-20. PubMed ID: 23657801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors.
    Yakovleva T; Sokolov V; Chu L; Tang W; Greasley PJ; Peilot Sjögren H; Johansson S; Peskov K; Helmlinger G; Boulton DW; Penland RC
    Diabetes Obes Metab; 2019 Dec; 21(12):2684-2693. PubMed ID: 31423699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a cell-based nonradioactive glucose uptake assay system for SGLT1 and SGLT2.
    Kanwal A; Singh SP; Grover P; Banerjee SK
    Anal Biochem; 2012 Oct; 429(1):70-5. PubMed ID: 22796500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental type II diabetes and related models of impaired glucose metabolism differentially regulate glucose transporters at the proximal tubule brush border membrane.
    Chichger H; Cleasby ME; Srai SK; Unwin RJ; Debnam ES; Marks J
    Exp Physiol; 2016 Jun; 101(6):731-42. PubMed ID: 27164183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitor binding in the human renal low- and high-affinity Na+/glucose cotransporters.
    Pajor AM; Randolph KM; Kerner SA; Smith CD
    J Pharmacol Exp Ther; 2008 Mar; 324(3):985-91. PubMed ID: 18063724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural Products as Lead Compounds for Sodium Glucose Cotransporter (SGLT) Inhibitors.
    Blaschek W
    Planta Med; 2017 Aug; 83(12-13):985-993. PubMed ID: 28395363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition.
    Dominguez Rieg JA; Rieg T
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):43-52. PubMed ID: 31081587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.